Is Scholar Rock Holding Corporation (SRRK) a Buy, Sell, or Hold?
Scholar Rock Holding Corporation
NASDAQ:SRRK
$53.78 USD
-$0.92 (-1.68%)
- Volume
- 1.24M
- Average Volume
- 1.47M
- Market Capitalization
- $6.44B
- P/E Ratio
- -15.59
- Dividend Yield
- 0.00%
- Price Target
- $58.00
- Year High
- $58.49
- Year Low
- $27.07
- Day High
- —
- Day Low
- —
- Payout Ratio
- $0.00
- Current Ratio
- $8.64
Industry, Sector & symbol
| Stock Exchange | NASDAQ |
| CEO | David L. Hallal |
| Industry | Biotechnology |
| Sector | Healthcare |
| Current Symbol | SRRK |
| CUSIP | 80706P103 |
| CIK | 0001727196 |
| Web | https://scholarrock.com |
| Phone | 857 259 3860 |
| Currency | USD |
| Employees | 289 |
| Country | US |
Liquidity
| Debt-to-Equity Ratio | 0.75 |
| Payout Ratio | 0.00 |
| Current Ratio | 8.64 |
| Quick Ratio | 8.64 |
| Cash Ratio | 7.22 |
Sales & Book Value
| Annual Sales | $- |
| Price / Sales | 0.00 |
| Cash Flow | -2.39 |
| Price / Cash Flow | -21.21 |
| Price / Book | 24.80 |
Price Target and Rating
| Average Stock Price Forecast | $58.00 |
| High Stock Price Forecast | $65.00 |
| Low Stock Price Forecast | $55.00 |
| Forecast Upside/Downside | -7.28% |
| Consensus Rating | Strong Sell |
| Rating Score(0-5) | 1 |
| Research Coverage | 12 Analysts |
Profitability
| EPS (Most Recent Fiscal Year) | $-3.29 |
| Trailing P/E Ratio | -15.59 |
| PEG Ratio | 0.58 |
| P/E Growth | 0.58 |
| Net Income | $-377.94M |
| Net Margin | 0.00% |
| Pretax Margin | 0.00% |
| Return on Equity | -163.52% |
| Return on Assets | -76.36% |
Financials Score
| AltmanZ Score | 10.29 |
| Piotroski Score | 1.00 |
| Working Capital | 455.64M |
| Total Assets | 535.25M |
| Ebit | -401.35M |
| Market Cap | 6.66B |
| Total Liabilities | 259.24M |
Poll Results
About Scholar Rock Holding Corporation (NASDAQ:SRRK) Stock
Scholar Rock Holding Corporation is a biopharmaceutical firm dedicated to discovering and advancing treatments for severe medical conditions by targeting the crucial role of protein growth factor signaling. Their lead therapeutic candidate, Apitegromab, an agent designed to inhibit the activation of latent myostatin, has successfully concluded Phase 3 clinical trials for spinal muscular atrophy (SMA). Another key program, SRK-181, is currently undergoing Phase 1 clinical assessment for tackling cancers that exhibit resistance to established checkpoint inhibitor treatments, including anti-PD-1 or anti-PD-L1 antibody therapies. Beyond these, the company cultivates a robust pipeline of innovative potential therapies, aiming to significantly improve the lives of individuals grappling with vari ... ous severe ailments, such as neurological muscle conditions, malignancies, and fibrotic disorders. In a strategic partnership, Scholar Rock is collaborating with Gilead Sciences, Inc. to identify and develop targeted inhibitors of transforming growth factor beta (TGF-beta) activation, specifically for addressing fibrotic diseases. Established in 2012, Scholar Rock Holding Corporation operates from its headquarters in Cambridge, Massachusetts.
2026-06-22 08:00:00
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Scholar Rock (NASDAQ: SRRK), a global biopharmaceutical company dedicated to improving the lives of children and adults with spinal muscular atrophy (SMA) and additional rare, severe, and debilitating neuromuscular diseases by applying its world-leading platform in myostatin biology, announced today that it will present new clinical data and research updates at Cure SMA's Annual SMA Research & Clinical Care Meeting being held June 24-26, 2026, in Orlando,.
Scholar Rock Reports New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
2026-06-12 16:15:00
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Scholar Rock (NASDAQ: SRRK; the “Company”) today announced that the company granted inducement equity awards covering an aggregate of 134,345 shares of its common stock to eleven newly hired employees, consisting of inducement stock options to purchase an aggregate of 50,936 shares of common stock and inducement restricted stock units, covering an aggregate of 83,409 shares of its common stock. The awards are subject to all terms and conditions and other provi.
2026-06-09 12:32:14
Scholar Rock Holding Corporation (SRRK) Presents at Goldman Sachs 47th Annual Global Healthcare Conference 2026 Transcript
Scholar Rock to Present at the Goldman Sachs 47th Annual Global Healthcare Conference
2026-05-26 09:30:00
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Scholar Rock (NASDAQ: SRRK), a global biopharmaceutical company dedicated to improving the lives of children and adults with spinal muscular atrophy (SMA) and additional rare, severe, and debilitating neuromuscular diseases by applying its leading platform in myostatin biology to advance musculoskeletal health, today announced that management will present at the Goldman Sachs 47th Annual Global Healthcare Conference in Miami, FL on Tuesday, June 9, 2026 at 10:.
Scholar Rock to Present at the 2026 Jefferies Global Healthcare Conference
2026-05-20 08:00:00
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Scholar Rock (NASDAQ: SRRK), a global biopharmaceutical company dedicated to improving the lives of children and adults with spinal muscular atrophy (SMA) and additional rare, severe, and debilitating neuromuscular diseases by applying its leading platform in myostatin biology to advance musculoskeletal health, today announced that management will present at the 2026 Jefferies Global Healthcare Conference in New York, NY on Wednesday, June 3, 2026 at 11:40 a.m.
Three Biotechs That Are Top Takeover Targets
2026-05-18 13:55:07
Eli Lilly (NYSE:LLY | LLY Price Prediction) is the stock everyone wants to talk about, and the reasons are obvious: Mounjaro revenue jumped 125% to $8.66 billion last quarter, the company raised full-year revenue guidance to $82 to $85 billion, and the market cap now sits at roughly $881.8 billion.
Scholar Rock Reports New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
2026-05-15 16:15:00
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Scholar Rock (NASDAQ: SRRK; the “Company”) today announced that the company granted inducement equity awards covering an aggregate of 38,481 shares of its common stock to six newly hired employees, consisting of inducement stock options to purchase an aggregate of 12,061 shares of common stock and inducement restricted stock units, covering an aggregate of 26,420 shares of its common stock. The awards are subject to all terms and conditions and other provision.
2026-05-12 14:20:48
Scholar Rock Holding Corporation (SRRK) Presents at Bank of America Global Healthcare Conference 2026 Transcript
Frequently Asked Questions
-
What is the current Scholar Rock Holding Corporation (SRRK) stock price?
-
Scholar Rock Holding Corporation(NASDAQ:SRRK) stock price is $53.78 in the last trading session. During the trading session, SRRK stock reached the peak price of $58.49 while $27.07 was the lowest point it dropped to. The percentage change in SRRK stock occurred in the recent session was --1.68% while the dollar amount for the price change in SRRK stock was -$-0.92.
-
SRRK's industry and sector of operation?
-
The NASDAQ listed SRRK is part of Biotechnology industry that operates in the broader Healthcare sector.
-
Who are the executives of SRRK?
-
Junlin | General Counsel & Corporate Secretary
Lisa Wyman | Chief Technical & Quality Officer
Rushmie Nofsinger | Vice President of Corporate Affairs & Investor Relations
David L. Hallal | Chief Executive Officer & Chairman of the Board
Caryn Parlavecchio | Chief Human Resources Officer -
How many employees does SRRK have?
-
Number of SRRK employees currently stands at 289. SRRK operates from 301 Binney Street, Cambridge, MA 02142, US.
-
Link for SRRK official website?
-
Official Website of SRRK is: https://scholarrock.com
-
How do I contact SRRK?
-
SRRK could be contacted at phone #857 259 3860 and can also be accessed through its website. SRRK operates from 301 Binney Street, Cambridge, MA 02142, US.
-
How many shares of SRRK are traded daily?
-
The average number of SRRK shares traded daily for last 3 months was 1.47M.
-
What is the market cap of SRRK currently?
-
The market value of SRRK currently stands at $6.44B with its latest stock price at $53.78